Non Opioid Pain Lin Health offers a non-opioid, neuroplastic pain management platform that targets enterprise buyers including health systems, clinics, and payers, presenting a scalable opportunity to integrate chronic pain care into existing care pathways.

Enterprise Growth A recent 11 million Series A, led by Proofpoint Capital with participation from .406 Ventures and Activate Capital, validates growth potential and supports expansion of Lin Health’s AI-based care platform across health networks.

Digital Telehealth The telehealth driven digital behavioral health platform launched in 2022 enables remote, tailored care plans and high-frequency coaching, a compelling selling point for health systems pursuing broader virtual chronic pain programs.

Operational Scale With revenue in the mid tens of millions and a headcount of 51-200, Lin Health demonstrates traction and scalability, backed by thousands of patients served in the last year, favorable for multi-site enterprise deals.

Market Positioning Industry recognition as a Consumer Wellness Rising Star and emphasis on non-pharmacological, neuroplastic pain differentiate Lin Health in a crowded market, creating collaboration opportunities with payers and providers in new regions.